Workshop_in_brief
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease. No present treatments can stop or reverse the disease, although Food and Drug Administration (FDA)-approved formulations may extend life by several months. As part of the information-gathering phase of a study on ALS, the National Academies Board on Health Care Services and Board on Health Sciences Policy cohosted a virtual public workshop series in August and September 2023 to identify key actions for the public, private, and nonprofit sectors to undertake to make ALS a livable disease within a decade. Speakers explored topics including access to high-quality, evidence-based ALS care, the lived experience of ALS, and ALS research and therapeutic development. This publication summarizes the presentations and discussion of the workshop.
14 pages
·
8.5 x 11
·
ISBN Ebook: 0-309-71314-5
DOI:
https://doi.org/10.17226/27395
National Academies of Sciences, Engineering, and Medicine. 2023. Amyotrophic Lateral Sclerosis: Accelerating Treatments and Improving Quality of Life: Proceedings of a Workshop—in Brief. Washington, DC: The National Academies Press.
Import this citation to: